

Paul J Catalano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2924612/publications.pdf>

Version: 2024-02-01

64
papers

3,135
citations

236925

25
h-index

175258

52
g-index

64
all docs

64
docs citations

64
times ranked

5300
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence and Predictors of Neurologic Death in Patients with Brain Metastases. <i>World Neurosurgery</i> , 2022, 162, e401-e415.	1.3	2
2	Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). <i>Journal of Clinical Oncology</i> , 2022, 40, 2913-2923.	1.6	40
3	Population-based estimates of survival among elderly patients with brain metastases. <i>Neuro-Oncology</i> , 2021, 23, 661-676.	1.2	25
4	Arterial Spin Labeled Perfusion MRI for the Evaluation of Response to Tyrosine Kinase Inhibition Therapy in Metastatic Renal Cell Carcinoma. <i>Radiology</i> , 2021, 298, 332-340.	7.3	13
5	Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1371-1380.	7.0	49
6	Seizures Among Patients With Brain Metastases. <i>Neurology</i> , 2021, 96, .	1.1	12
7	ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	29
8	Assessing ablation margins of FDG-avid liver tumors during PET/CT-guided thermal ablation procedures: a retrospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2914-2924.	6.4	14
9	F-18 FDG perfusion PET: intraprocedural assessment of the liver tumor ablation margin. <i>Abdominal Radiology</i> , 2021, 46, 3437-3447.	2.1	8
10	Emergency department visits and inpatient hospitalizations among older patients with brain metastases: a dual population- and institution-level analysis. <i>Neuro-Oncology Practice</i> , 2021, 8, 569-580.	1.6	1
11	Lung Cancer Strategist Program: A novel care delivery model to improve timeliness of diagnosis and treatment in high-risk patients. <i>Healthcare</i> , 2021, 9, 100563.	1.3	2
12	Master Protocol Trial Design for Efficient and Rational Evaluation of Novel Therapeutic Oncology Devices. <i>Journal of the National Cancer Institute</i> , 2020, 112, 229-237.	6.3	15
13	Utility of claims data for identification of date of diagnosis of brain metastases. <i>Neuro-Oncology</i> , 2020, 22, 575-576.	1.2	12
14	Doxorubicin and subsequent risk of cardiovascular diseases among survivors of diffuse large B-cell lymphoma in Hong Kong. <i>Blood Advances</i> , 2020, 4, 5107-5117.	5.2	8
15	Utility of claims data for delineation of intracranial treatment among patients with brain metastases. <i>Neuro-Oncology</i> , 2020, 22, 1547-1548.	1.2	2
16	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. <i>Nature Medicine</i> , 2020, 26, 909-918.	30.7	488
17	Prescription of memantine during non-stereotactic, brain-directed radiation among patients with brain metastases: a population-based study. <i>Journal of Neuro-Oncology</i> , 2020, 148, 509-517.	2.9	7
18	Racial disparities in supportive medication use among older patients with brain metastases: a population-based analysis. <i>Neuro-Oncology</i> , 2020, 22, 1339-1347.	1.2	27

#	ARTICLE	IF	CITATIONS
19	Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1660-1667.	2.5	127
20	A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 132-139.	0.8	8
21	Effects of Postmastectomy Radiation Therapy on Immediate Tissue Expander and Acellular Dermal Matrix Reconstruction: Results of a Prospective Clinical Trial. <i>Practical Radiation Oncology</i> , 2019, 9, 338-346.	2.1	7
22	irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 2174-2184.	7.0	80
23	Local control after brain-directed radiation in patients with cystic versus solid brain metastases. <i>Journal of Neuro-Oncology</i> , 2019, 142, 355-363.	2.9	13
24	Neurosurgical Resection and Stereotactic Radiation Versus Stereotactic Radiation Alone in Patients with a Single or Solitary Brain Metastasis. <i>World Neurosurgery</i> , 2019, 122, e1557-e1561.	1.3	17
25	Cabozantinib in Patients with Advanced Merkel Cell Carcinoma. <i>Oncologist</i> , 2018, 23, 814-821.	3.7	30
26	Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. <i>Radiotherapy and Oncology</i> , 2018, 126, 511-518.	0.6	18
27	Outcomes by EGFR, KRAS, and ALK Genotype After Combined Modality Therapy for Locally Advanced Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2018, 2, 1-18.	3.0	5
28	Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 341-348.	1.9	5
29	Funding Support and Principal Investigator Leadership of Oncology Clinical Trials Using Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 34-43.	0.8	9
30	Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 137-145.	0.8	24
31	Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. <i>Neuro-Oncology</i> , 2017, 19, 1511-1521.	1.2	483
32	Brain Metastases in Newly Diagnosed Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 1069.	7.1	224
33	The Intensive Palliative Care Unit: Changing Outcomes for Hospitalized Cancer Patients in an Academic Medical Center. <i>Journal of Palliative Medicine</i> , 2017, 20, 285-289.	1.1	15
34	Patient-oriented toxicity endpoints after head and neck reirradiation with intensity modulated radiation therapy. <i>Oral Oncology</i> , 2017, 73, 160-165.	1.5	7
35	MR- versus CT-based high-dose-rate interstitial brachytherapy for vaginal recurrence of endometrial cancer. <i>Brachytherapy</i> , 2017, 16, 1159-1168.	0.5	32
36	Radiation toxicity in patients with collagen vascular disease and intrathoracic malignancy treated with modern radiation techniques. <i>Radiotherapy and Oncology</i> , 2017, 125, 301-309.	0.6	11

#	ARTICLE	IF	CITATIONS
37	The risk of lymphedema after postoperative radiation therapy in endometrial cancer. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e4.	2.2	25
38	Comparison of performance of various tumor response criteria in assessment of sunitinib activity in advanced gastrointestinal stromal tumors. <i>Clinical Imaging</i> , 2016, 40, 880-884.	1.5	9
39	Healthier Standards for School Meals and Snacks. <i>American Journal of Preventive Medicine</i> , 2016, 51, 485-492.	3.0	28
40	The need for preoperative baseline arm measurement to accurately quantify breast cancer-related lymphedema. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 229-240.	2.5	60
41	Outcomes with volume-based dose specification in CT-planned high-dose-rate brachytherapy for stage I-II cervical carcinoma: A 10-year institutional experience. <i>Gynecologic Oncology</i> , 2016, 143, 545-551.	1.4	13
42	Hepatic Microwave Ablation Zone Size: Correlation with Total Energy, Net Energy, and Manufacturer-Provided Chart Predictions. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 1389-1396.	0.5	17
43	Patterns of failure after reirradiation with intensity-modulated radiation therapy and the competing risk of out-of-field recurrences. <i>Oral Oncology</i> , 2016, 61, 19-26.	1.5	20
44	Prognostic importance of human papillomavirus (HPV) and p16 positivity in squamous cell carcinoma of the vulva treated with radiotherapy. <i>Gynecologic Oncology</i> , 2016, 142, 293-298.	1.4	87
45	Body Mass Index and Locoregional Recurrence in Women with Early-Stage Breast Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 3870-3879.	1.5	28
46	Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 421-428.	4.9	10
47	Outcomes with image-based interstitial brachytherapy for vaginal cancer. <i>Radiotherapy and Oncology</i> , 2016, 120, 486-492.	0.6	42
48	Eastern Cooperative Oncology Group and American College of Radiology Imaging Network Randomized Phase 2 Trial of Neoadjuvant Preoperative Paclitaxel/Cisplatin/Radiation Therapy (RT) or Irinotecan/Cisplatin/RT in Esophageal Adenocarcinoma: Long-Term Outcome and Implications for Trial Design. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 738-746.	0.8	16
49	Validation and Application of the Mass Balance Model To Determine the Effectiveness of Portable Air Purifiers in Removing Ultrafine and Submicrometer Particles in an Apartment. <i>Environmental Science & Technology</i> , 2015, 49, 9592-9599.	10.0	13
50	Ipilimumab and cranial radiation in metastatic melanoma patients: a case series and review. , 2015, 3, 50.		84
51	Changing prognostic significance of tumor stage and nodal stage in patients with squamous cell carcinoma of the oropharynx in the human papillomavirus era. <i>Cancer</i> , 2015, 121, 2594-2602.	4.1	53
52	Effects of Choice Architecture and Chef-Enhanced Meals on the Selection and Consumption of Healthier School Foods. <i>JAMA Pediatrics</i> , 2015, 169, 431.	6.2	97
53	Local Therapies for Brain Metastases, Competing Risks, and Overall Survival. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 718-720.	0.8	8
54	Rectal bleeding after radiation therapy for endometrial cancer. <i>Radiotherapy and Oncology</i> , 2015, 115, 240-245.	0.6	7

#	ARTICLE	IF	CITATIONS
55	Prospective assessment of deep inspiration breath-hold using 3-dimensional surface tracking for irradiation of left-sided breast cancer. <i>Practical Radiation Oncology</i> , 2015, 5, 358-365.	2.1	49
56	Dosimetric Inhomogeneity Predicts for Long-Term Breast Pain After Breast-Conserving Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 1087-1095.	0.8	21
57	Rates and Durability of Response to Salvage Radiation Therapy Among Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 223-231.	0.8	40
58	Outcomes by Tumor Histology and KRAS Mutation Status After Lung Stereotactic Body Radiation Therapy for Early-Stage Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2015, 16, 24-32.	2.6	67
59	Percutaneous Imaging-Guided Cryoablation of Liver Tumors: Predicting Local Progression on 24-Hour MRI. <i>American Journal of Roentgenology</i> , 2014, 203, W181-W191.	2.2	45
60	Percutaneous treatment of hepatocellular carcinoma in patients with cirrhosis: A comparison of the safety of cryoablation and radiofrequency ablation. <i>European Journal of Radiology</i> , 2014, 83, 632-638.	2.6	40
61	Impact of the New U.S. Department of Agriculture School Meal Standards on Food Selection, Consumption, and Waste. <i>American Journal of Preventive Medicine</i> , 2014, 46, 388-394.	3.0	198
62	Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. <i>Neuro-Oncology</i> , 2014, 16, 1547-1553.	1.2	80
63	Few Changes in Food Security and Dietary Intake From Short-term Participation in the Supplemental Nutrition Assistance Program Among Low-income Massachusetts Adults. <i>Journal of Nutrition Education and Behavior</i> , 2014, 46, 68-74.	0.7	31
64	Representativeness of Participants in the Cancer Care Outcomes Research and Surveillance Consortium Relative to the Surveillance, Epidemiology, and End Results Program. <i>Medical Care</i> , 2013, 51, e9-e15.	2.4	78